"Hasumi vaccine, Immuno-competent, vaccine"

The approach is very different from the other clinics.
We are using immune therapy in our bodies when possible. Lack of popularity in the body's immune therapy Oncology show more of the road usually does not work.

For all drugs, including cancer, only after a clinical trial to follow strict guidelines set by regulatory agencies such as FDA.
Until now most of the mandate of the immune therapy will be tested only after failure of conventional chemotherapy.

At present this patient who suffered serious depression, a result of the second cancer.
Conditions like this is extraordinary, immune therapy can be used as the first line treatment, before chemotherapy, radiation, and also some of the operation, which menampilakan face is more active.

Anti-cancer vaccine: It can also be given at this time when deemed appropriate. Stimulate immunity in the body of the procedure, often working together with the vaccine, each augmenting the other.
Several types of vaccine are available, also made from a patient's own tissue or blood components, while the other common vaccines produced through the use of a network of cancer growth in network culture, such as Hasumi vaccine.
Variable or sometimes lack of activity seen with this vaccine in general clinical settings is usually the result of its use in patients who Immuno-suppressed and therefore can not respond to treatment.
We only use the vaccine in the Immuno-Immuno-competent or recovered patients.